Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
It can be difficult to prioritize getting organized, but taking precautionary steps can actually save you time in the long run. To help, here are nine organization strategies for busy professionals.
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.
Cassava Sciences CEO Remi Barbier is hitting back at The New York Times, calling out the newspaper for an article that he claims misrepresented the research of his company.
Pheast, Apertura and Reify Health are BioSpace’s top financial winners this week. Read on to see what money can do!
All development and commercialization rights for MP0310, a clinical stage immunomodulator intended to treat solid tumors, will be reverted to Molecular Partners.
Pheast Therapeutics launched today with $76 million in Series A financing. Pheast is focused on developing cancer checkpoint therapies to fight malignant cells, focusing on ovarian and breast cancers.
Successful biotech companies have a certain way of thinking that propels everyone working there beyond day-to-day concerns and enables them to do great things. BioSpace highlights nine commonalities.
Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.
How many boosters are enough to protect against COVID-19 infection? This question has been at the forefront of the minds of everyone as news crops up about yearly boosters.
Gamida Cell reported that the FDA had lifted its clinical hold on its cryopreserved formulation of GDA-201. It expects to launch a Phase I/II drug trial for those indications this year.
With $67 million in Series A financing, newly-launched Apertura plans to develop genetic medicines using technologies that address key limitations of gene delivery and expression.
The war has shattered plans for a variety of clinical trials, but Roche is particularly concerned about fenebrutinib, a drug it is developing for multiple sclerosis (MS).